Shots:

• The P-III BRAVE-AA2 study involves assessing Baricitinib (2mg & 4mg- qd) vs PBO in 546 adults with a SALT score ≥ 50 (i.e.- who had ≥50% scalp hair loss) and a current episode of severe AA lasting at least 6mos. but no >8yrs.
• The P-III study met its 1EPs @36wks. and demonstrated significant improvement in scalp hair regrowth. The findings from additional P-III study will be available in H1’21
• Baricitinib is an oral JAK inhibitor and commercially available as Olumiant in the US and 70 + countries for mod. to sev. active RA. The therapy is also approved for AD in the EU and Japan and has received the US FDA’s BTD for AA

 ­ Ref: Lilly | Image: Eli Lilly